AstraZeneca vaccine, AZD1222, developed in collaboration with the University of Oxford, has an average efficacy of 70% in protecting against the coronavirus, according to the company’s press release. Interim analysis of clinical trials involving 131 COVID-19 cases in the UK and Brazil showed no hospitalizations or severe cases of COVID-19 in participants treated with AZD1222.
- AstraZeneca has indicated that additional analysis of vaccine data could alter average efficacy results and help to know the duration of protection.
- The company would prepare the regulatory submission of the data to health authorities worldwide that have a framework for conditional or early vaccine approval.
- AstraZeneca vaccine can be kept at normal refrigerator temperatures of 36-46 degrees Fahrenheit for at least six months and administered within existing healthcare settings.
- The company’s vaccine was assessed in two dosing regimens, one showing an effectiveness of 90% when trial participants received a half dose, followed by a full dose at least one month apart.
- In the second trial, at least one month apart, two doses were administered, showing a 62% efficacy.
- AstraZeneca vaccine comes after a string of other vaccine developments from Pfizer, BioNTech, and Moderna.
AstraZeneca stock is currently declining. AZN: LON is down 3.58%